ArticleCureus2024
Vitamin D Deficiency and Avascular Necrosis in Patients With Sickle Cell Disease: A Retrospective Cohort Study.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Sickle cell disease (SCD) is an inherited hemoglobinopathy with complex multi-systemic involvement. Avascular necrosis (AVN) is a devastating complication among patients with SCD. Vitamin D deficiency (VDD) is a common finding in SCD patients. However, there is a paucity of research that evaluates the potential role of VDD as a risk factor for AVN in patients with SCD. This study aimed to assess the association between VDD and AVN and determine the patterns of presentation, risk factors, diagnosis, and treatment of AVN in patients with SCD. Methods We conducted a retrospective cohort study of consecutive SCD patients diagnosed with VDD from January 2020 to December 2022 at Prince Sultan Medical Military City (PSMMC), Riyadh, Saudi Arabia. Inclusion criteria: (1) adults and children with confirmed SCD and (2) tested for VDD. We excluded patients who underwent bone marrow transplants. The associations were assessed using the chi-square test. Logistic regression was performed to control for confounding. Results The study included 711 eligible patients; 271 (38%) were children. VDD affected 301/711 (42.3%). VDD was noticed in 32.2% and 48.1% of children and adults, respectively. AVN was diagnosed in 127/711 (17.9%) patients. The mean age at AVN diagnosis was 30.9 ± 11 years. The most common presentation of AVN was chronic joint pain (> 95%). The most frequently affected joint was the hip (86%). The majority of patients (76.4%) were late in stage at diagnosis of AVN (III/IV). Patients with a history of VDD were significantly associated with a higher risk of AVN (p < 0.001). Using multivariate logistic regression, SCD patients with VDD have 9.79 times the odds of AVN compared with SCD patients without VDD (OR 9.79; 95% CI: 5.25 - 18.26). Other statistically significant risk factors for AVN included frequent vaso-occlusive crises, older age, history of acute chest syndrome, and high body mass index. Conclusion AVN is a significant cause of morbidity in our SCD cohort. Most of the patients had advanced AVN disease. VDD is an independent risk factor for the occurrence of AVN. Well-designed randomized trials are required to determine the effect of vitamin D supplementation in reducing AVN in patients with SCD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.